Advertisement

Surveillance for Hepatocellular Carcinoma

  • Eleanor J. Taylor
  • Ian A. RoweEmail author
Chapter

Abstract

Surveillance for hepatocellular carcinoma (HCC) in patients with cirrhosis is recommended with the aim to reduce mortality. The evidence that supports surveillance is of low quality, and the test used, 6-monthly ultrasound scanning, has inherent limitations that reduce its efficacy. Those limitations affect both sensitivity, meaning that not all early stage cancer is diagnosed, and also specificity, leading to false-positive testing and downstream harm. The factors that limit the effectiveness of surveillance are discussed in this chapter, together with proposals to improve the outcomes for patients with cirrhosis and undergoing surveillance for HCC.

Keywords

Liver cancer Benefit Harm Ultrasound AFP 

References

  1. 1.
    Global Burden of Disease Mortality, Causes of Death Collaboration. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71.CrossRefGoogle Scholar
  2. 2.
    El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–27.CrossRefGoogle Scholar
  3. 3.
    European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43.Google Scholar
  4. 4.
    NICE. Clinical Guideline 50: Cirrhosis in over 16s: Assessment and management. 2016; https://www.nice.org.uk/guidance/ng50/evidence/full-guideline-2546537581. Accessed 12 Jul 2016.
  5. 5.
    Heimbach JK, Kulik LM, Finn R, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2017;67(1):358–80.CrossRefGoogle Scholar
  6. 6.
    Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–53.CrossRefGoogle Scholar
  7. 7.
    Wong VW, Janssen HL. Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection? J Hepatol. 2015;63(3):722–32.CrossRefGoogle Scholar
  8. 8.
    Lederle FA, Pocha C. Screening for liver cancer: the rush to judgment. Ann Intern Med. 2012;156(5):387–9.CrossRefGoogle Scholar
  9. 9.
    Kansagara D, Papak J, Pasha AS, et al. Screening for hepatocellular carcinoma in chronic liver disease: a systematic review. Ann Intern Med. 2014;161(4):261–9.CrossRefGoogle Scholar
  10. 10.
    Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11(4):e1001624.CrossRefGoogle Scholar
  11. 11.
    Mittal S, Kanwal F, Ying J, et al. Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort. J Hepatol. 2016;65(6):1148–54.CrossRefGoogle Scholar
  12. 12.
    Cucchetti A, Trevisani F, Pecorelli A, et al. Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. J Hepatol. 2014;61(2):333–41.CrossRefGoogle Scholar
  13. 13.
    Davila JA, Henderson L, Kramer JR, et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med. 2011;154(2):85–93.CrossRefGoogle Scholar
  14. 14.
    Cross TJ, Villanueva A, Shetty S, et al. A national survey of the provision of ultrasound surveillance for the detection of hepatocellular carcinoma. Frontline Gastroenterol. 2016;7:82–9.Google Scholar
  15. 15.
    Poustchi H, Farrell GC, Strasser SI, Lee AU, McCaughan GW, George J. Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology. 2011;54(6):1998–2004.CrossRefGoogle Scholar
  16. 16.
    Taylor EJ, Jones RL, Guthrie JA, Rowe IA. Modeling the benefits and harms of surveillance for hepatocellular carcinoma: Information to support informed choices. Hepatology. 2017;66(5):1546–55.CrossRefGoogle Scholar
  17. 17.
    Yang JD, Mannalithara A, Piscitello AJ, et al. Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. Hepatology. 2017;68(1):78–88.CrossRefGoogle Scholar
  18. 18.
    Atiq O, Tiro J, Yopp AC, et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology. 2016;65(4):1196–205.CrossRefGoogle Scholar
  19. 19.
    Trinchet JC, Chaffaut C, Bourcier V, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology. 2011;54(6):1987–97.CrossRefGoogle Scholar
  20. 20.
    Farvardin S, Patel J, Khambaty M, et al. Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. Hepatology. 2016;65(3):875–84.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Liver UnitSt. James’s University HospitalLeedsUK
  2. 2.Leeds Institute for Data AnalyticsUniversity of LeedsLeedsUK

Personalised recommendations